<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03737565</url>
  </required_header>
  <id_info>
    <org_study_id>RETO 320</org_study_id>
    <nct_id>NCT03737565</nct_id>
  </id_info>
  <brief_title>Evaluation of the Safety and Efficacy of Titanium-nitric Oxide-coated Stent (Optimax®) in Patients With Lesions With a Low Risk of Restenosis (Diameter ≥ 3.0 mm and Length ≤ 20 mm)</brief_title>
  <acronym>RETO 320</acronym>
  <official_title>Prospective, Multicenter and Observational Registry for the Evaluation of the Safety and Efficacy of Titanium-nitric Oxide-coated Stent (Optimax®) in Patients With Lesions With a Low Risk of Restenosis (Diameter ≥ 3.0 mm and Length ≤ 20 mm) (Reto 320 Study)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fundación EPIC</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fundación EPIC</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This prospective registry is intended to evaluate the safety and efficacy of the Optimax®
      stent.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This prospective registry is intended to evaluate the safety and efficacy of the Optimax®
      stent in de novo coronary lesions with reference diameter ≥ 3.0 mm and Length ≤ 20 mm.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 17, 2019</start_date>
  <completion_date type="Anticipated">April 15, 2020</completion_date>
  <primary_completion_date type="Anticipated">January 15, 2020</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>12 Months</target_duration>
  <primary_outcome>
    <measure>Safety. The number of composite events of cardiac.</measure>
    <time_frame>6 and 12 month</time_frame>
    <description>The number of composite events of cardiac death, myocardial infarction (MI) and stent thrombosis (Academic Research Consortium definitive/probable).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Efficacy: Incidence of clinically driven target lesion revascularization (TLR).</measure>
    <time_frame>6 and 12 month</time_frame>
    <description>Incidence of clinically driven target lesion revascularization (TLR).Defined as any repeat percutaneous intervention of the target lesion or bypass surgery of the target vessel performed for restenosis or other complication of the target lesion.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>All death.</measure>
    <time_frame>6 and 12 month</time_frame>
    <description>Systemic embolism, Major bleeding event (BARC ≥ 2).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiac death.</measure>
    <time_frame>6 and 12 month</time_frame>
    <description>Cardiac death.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Target Vessel revascularization.</measure>
    <time_frame>6 and 12 month</time_frame>
    <description>Target Vessel revascularization.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Target lesion revascularization.</measure>
    <time_frame>6 and 12 month</time_frame>
    <description>Target lesion revascularization.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stent thrombosis (ARC definite/probable).</measure>
    <time_frame>6 and 12 month</time_frame>
    <description>Stent thrombosis (ARC definite/probable).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Major bleeding event (BARC type 2-5).</measure>
    <time_frame>6 and 12 month</time_frame>
    <description>Major bleeding event (BARC type 2-5).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stroke.</measure>
    <time_frame>6 and 12 month</time_frame>
    <description>Stroke.</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">350</enrollment>
  <condition>Coronary Artery Disease</condition>
  <arm_group>
    <arm_group_label>Coronary Artery Disease</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Optimax stent®</intervention_name>
    <description>Percutaneous coronary intervention with Optimax stent®</description>
    <arm_group_label>Coronary Artery Disease</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with de novo coronary lesion treated with Optimax® stent, reference diameter = 3.0
        mm and length ≤ 20 mm.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with age ≥ 18 years old.

          -  Patients with de novo coronary lesion treated with Optimax® stent, reference diameter
             = 3.0 mm and length ≤ 20 mm.

          -  Informed consent signed.

        Exclusion Criteria:

          -  Refusal of the patient to participate at the study.

          -  Treatment of other injuries that do not meet the conditions (3x20).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Fundación EPIC</last_name>
    <phone>+34987876135</phone>
    <email>admin@fundacionepic.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hospital de Mérida</name>
      <address>
        <city>Mérida</city>
        <state>Badajoz</state>
        <zip>06800</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Vall d`Hebron</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital San Pedro de Alcántara</name>
      <address>
        <city>Cáceres</city>
        <zip>10003</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario de León</name>
      <address>
        <city>León</city>
        <zip>24080</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari Arnau de Vilanova</name>
      <address>
        <city>Lleida</city>
        <zip>25198</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <results_reference>
    <citation>López-Mínguez JR, Nogales-Asensio JM, Romani S, Rivero-Crespo F, Aragón-Extremera VM, Jiménez-Mazuecos JM, Carrasco F, Oteo-Domínguez JF, Bosa-Ojeda F, Gómez-Hospital JA. TIOMAX: A Spanish Multicenter Registry of the real-world use of the TItanium OptiMAX(®) biostent: TIOMAX: Registro Español Multicéntrico Del Biostent De Titanio OptiMAX(®) En La Vida Real. Catheter Cardiovasc Interv. 2018 Aug 1;92(2):261-268. doi: 10.1002/ccd.27326. Epub 2017 Sep 30.</citation>
    <PMID>28963751</PMID>
  </results_reference>
  <results_reference>
    <citation>Karjalainen PP, Nammas W, Ylitalo A, de Bruyne B, Lalmand J, de Belder A, Rivero-Crespo F, Kervinen K, Airaksinen JKE. Long-term clinical outcome of titanium-nitride-oxide-coated stents versus everolimus-eluting stents in acute coronary syndrome: Final report of the BASE ACS trial. Int J Cardiol. 2016 Nov 1;222:275-280. doi: 10.1016/j.ijcard.2016.07.267. Epub 2016 Aug 1.</citation>
    <PMID>27497110</PMID>
  </results_reference>
  <results_reference>
    <citation>Colkesen EB, Eefting FD, Rensing BJ, Suttorp MJ, Ten Berg JM, Karjalainen PP, Van Der Heyden JA. TIDES-ACS Trial: comparison of titanium-nitride-oxide coated bio-active-stent to the drug (everolimus)-eluting stent in acute coronary syndrome. Study design and objectives. Minerva Cardioangiol. 2015 Feb;63(1):21-9.</citation>
    <PMID>25670057</PMID>
  </results_reference>
  <verification_date>January 2019</verification_date>
  <study_first_submitted>November 8, 2018</study_first_submitted>
  <study_first_submitted_qc>November 8, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">November 9, 2018</study_first_posted>
  <last_update_submitted>March 30, 2019</last_update_submitted>
  <last_update_submitted_qc>March 30, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">April 2, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Cobalt-chromium</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tryptophan</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

